David May, MD, PhD, FACC, and Arthur Garson, Jr, MD, MPH, explore the most common cardiovascular conditions linked to hospital readmissions during transitions of care scenarios.
Dr Garson, Jr, says that congestive heart failure and myocardial infarction result in unnecessary hospital readmissions. He discusses how, in an effort to reduce readmission rates, the Centers for Medicare & Medicaid Services has instituted penalties for readmissions linked to both conditions.
In addition to heart failure and myocardial infarction, Dr May adds that atrial fibrillation, venous thromboembolism, and pulmonary embolism also have high readmission rates.
Dr May suggests that complex medication regimens and increased anxiety lead patients and their family members to seek hospital care in situations where it may not be necessary. He explains that it is the responsibility of the healthcare professional to provide medical education and facilitate proper transitions of care, especially when caring for patients who are treated with complex medication regimens because they have chronic, ongoing medical complications.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD
April 8th 2025Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
Read More